AI-generated analysis. Always verify with the original filing.
Immuneering Corporation reported a net loss of $56.0 million for fiscal year 2025, a slight improvement from a $61.0 million loss in 2024. The company generated no revenue, with total operating expenses of $59.4 million, primarily driven by $42.0 million in research and development and $17.3 million in general and administrative costs. The net loss per share was -$1.00. The company ended the year with a strong liquidity position, holding $217.0 million in cash, cash equivalents, and marketable securities, which it believes is sufficient to fund operations into 2029. Key forward-looking activities include the planned initiation of the Phase 3 MAPKeeper 301 trial for its lead candidate atebimetinib in mid-2026.
EPS
-$1.00
Net Income
-$56.0M